Momenta Pharmaceuticals (MNTA) 10.69 $MNTA
Biotech Equities Under Review -- Research on Achillion Pharma, Mast Therapeutics, Alkermes, and Momenta Pharma
PR Newswire - Fri May 09, 12:30PM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,550.97, and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished positive. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Mast Therapeutics Inc. (NYSE MKT: MSTX), Alkermes PLC (NASDAQ: ALKS) and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Free technical research on ACHN, MSTX, ALKS and MNTA can be downloaded upon signing up at:
Narrower-than-Expected Loss at Momenta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 11:10AM CDT
Momenta Pharma (MNTA) reported 1Q14 net loss per share of 53 cents, narrower than the Zacks Consensus Estimate of a loss of 55 cents
Why Momenta Pharmaceuticals, Inc. Shares Sank
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 1:03PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Momenta Pharmaceuticals , a biotechnology...
Momenta Pharmaceuticals Shares Down 26.2% Since SmarTrend's Sell Call (MNTA)
Comtex SmarTrend(R) - Tue May 06, 9:21AM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 2 months, Momenta Pharmaceuticals has returned 26.19% as of today's recent price of $10.92.
Momenta Pharmaceuticals Reports First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 9:16AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2014.
Momenta Pharmaceuticals Announces Presentation of Data Supporting Sialylation Platform
GlobeNewswire - Fri May 02, 7:47AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will present its approach to designing novel therapeutics by applying site-specific sialylation to Fc glycans in IVIg, monoclonal antibodies, and other recombinant Fc-containing proteins, in a presentation entitled "Embracing Complexity: Understanding IVIg to Rationally Engineer Novel Therapeutics". The presentation will be given by Tony Manning, Ph.D., Vice President of Research at Momenta, at 12:10 pm on Monday, May 5, 2014 at the PEGS annual meeting in Boston.
Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor Conferences
GlobeNewswire - Wed Apr 30, 3:12PM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at three upcoming investor conferences.
25.9% Return Seen to Date on SmarTrend Momenta Pharmaceuticals Call (MNTA)
Comtex SmarTrend(R) - Mon Apr 28, 5:04PM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 2 months, Momenta Pharmaceuticals has returned 25.85% as of today's recent price of $10.97.
Teva's Copaxone: Perspectives From a Patient and Investor
Anders Bylund, The Motley Fool - Motley Fool - Fri Apr 25, 1:30PM CDT
I was diagnosed with multiple sclerosis five years ago. My neurologist asked me to choose one of the classic CRAB (Copaxone, Rebif, Avonex, or Betaseron) therapies, and I settled on Teva Pharmaceutical Industries ' blockbuster Copaxone treatment....
Global Metastatic Pancreatic Cancer Therapeutics Pipeline Review 2014 - Analysis of 27 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gctlqw/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Adherex Technologies Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - FibroGen, Inc. - Novartis AG - Pfizer Inc. - Celgene Corporation - Bayer AG - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Insys Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - AB Science - Oncovir, Inc. - ParinGenix, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. Drug Profiles - paclitaxel albumin-bound - irinotecan sucrosofate liposomal - masitinib - cisplatin liposomal - cisplatin - refametinib - selumetinib sulfate - trametinib dimethyl sulfoxide - docetaxel - paclitaxel albumin-bound - ganetespib - RX-0201 - irinotecan sucrosofate liposomal - PGX-100 - lurbinectedin - yttrium Y 90 clivatuzumab tetraxetan - Cancer Inhibitor Macrobeads - TL-118 - LY-2090314 - hydroxychloroquine - LY-2495655 - PEGPH-20 - M-402 - pentamidine isethionate - veliparib - galunisertib - ADH-1 - FG-3019 - demcizumab - LCL-161 For more information visit http://www.researchandmarkets.com/research/gctlqw/metastatic
Supreme Court Denies Teva's Request - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 3:35PM CDT
The U.S. Supreme Court denied Teva's appeal of a decision from the U.S. Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 covering Teva's relapsing-remitting multiple sclerosis (RRMS) product, Copaxone 20mg/mL.
Shares of MNTA Down 21.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 21, 11:04AM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 2 months, Momenta Pharmaceuticals has returned 21.12% as of today's recent price of $11.67.
Why Teva (TEVA) Stock Is Lower
at The Street - Mon Apr 21, 7:38AM CDT
Shares of Teva Pharmaceuticals (TEVA) are down in pre-market trade after U.S. Supreme Court Chief Justice Roberts rejected the company's bid to block generic versions of its Copaxone multiple-sclerosis drug while the court hears the company's appeal...
Court declines to block drug ruling in patent case
By SAM HANANEL - AP - Fri Apr 18, 3:39PM CDT
WASHINGTON (AP) — Supreme Court Chief Justice John Roberts on Friday declined to temporarily block a lower court ruling that opens the world's best-selling multiple sclerosis drug to competition from generic rivals next month.
AMAG Pharmaceuticals Announces Appointment of Jim Sulat to Its Board of Directors and the Transition of Chairman Role to Gino Santini
GlobeNewswire - Wed Apr 16, 6:49PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new appointments to its board of directors. Current board member, Gino Santini, has been elected, by unanimous vote, to chairman of the board of directors, effective immediately, taking over for Mike Narachi. Mr. Narachi informed the board that, after eight years of service, he has decided not to stand for re-election at this year's upcoming annual shareholder meeting in May 2014. In addition, James R. Sulat has been elected to serve as a new member of the board of directors, effective immediately.
World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others
M2 - Wed Apr 16, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5qb5x5/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others), predicts a market of nearly $5 billion dollars in the next five years. It's not the first prediction that has been made about the market for generic forms of biopharmaceutical drugs, but according to this report a multi-billion dollar market for biosimilars will arrive in the next five years. The healthcare organization says it's in almost everyone's interest - payors, governments, providers and patients seeking low-cost alternatives to the most expensive and effective therapies. The generic biologic drug market presents many more challenges than the traditional generic market and regulatory restrictions remain. Generic biological drugs are more difficult to produce and a few firms have the expertise. Unlike generics, they are not the exact same as the brand, they have a similar structure and function. Insulin, blood products and monoclonal antibodies (mAbs) are expected to show the most potential for generic equivalent products with blood products leading in revenues. The EU is the first in the world to have defined a policy and legal framework for biosimilars. Absence of such regulation and biosimilars approval process in other countries, in particular in the United States, can lead to a competitive advantage to the EU biosimilars industry, according to the report. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others).contains predictions of biosimilar markets in certain biologic drug segments, as well as market by regions. The report contains specific forecasts for each type of biopharmaceutical and breaks out forecasts by region. Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3Sbio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Biopartners Gmbh - Bio Sidus S.A. - Bioxpress Therapeutics S.A - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy'S Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals Usa, Inc - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance Genemedix Plc - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International Gmbh - Sandoz International Gmbh - Stada Arzneimittel Ag - Teva Pharmaceutical Industries, Ltd. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/5q...rld_market
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 15, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Momenta Pharmaceuticals Announces Date of First Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Apr 15, 3:05PM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2014 before the U.S. financial markets open on Tuesday, May 6, 2014.
The Supreme Court Will Decide the Fate of a Blockbuster
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
Recently, Teva Pharmaceuticals lost a patent lawsuit over its multiple sclerosis drug Copaxone, which makes up a crucial 40% of the company's income. However, the U.S. Supreme Court has announced that it will hear Teva's appeal of this Appeals...
Momenta Pharmaceuticals Down 29.9% Since SmarTrend Downtrend Call (MNTA)
Comtex SmarTrend(R) - Fri Apr 11, 10:00AM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 1 month, Momenta Pharmaceuticals has returned 29.91% as of today's recent price of $10.37.
Biotech Equities Under Review -- Research on Achillion Pharma, Mast Therapeutics, Alkermes, and Momenta Pharma
PR Newswire - Fri May 09, 12:30PM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,550.97, and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished positive. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Mast Therapeutics Inc. (NYSE MKT: MSTX), Alkermes PLC (NASDAQ: ALKS) and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Free technical research on ACHN, MSTX, ALKS and MNTA can be downloaded upon signing up at:
Narrower-than-Expected Loss at Momenta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 11:10AM CDT
Momenta Pharma (MNTA) reported 1Q14 net loss per share of 53 cents, narrower than the Zacks Consensus Estimate of a loss of 55 cents
Why Momenta Pharmaceuticals, Inc. Shares Sank
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 1:03PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Momenta Pharmaceuticals , a biotechnology...
Momenta Pharmaceuticals Shares Down 26.2% Since SmarTrend's Sell Call (MNTA)
Comtex SmarTrend(R) - Tue May 06, 9:21AM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 2 months, Momenta Pharmaceuticals has returned 26.19% as of today's recent price of $10.92.
Momenta Pharmaceuticals Reports First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 9:16AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2014.
Momenta Pharmaceuticals Announces Presentation of Data Supporting Sialylation Platform
GlobeNewswire - Fri May 02, 7:47AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will present its approach to designing novel therapeutics by applying site-specific sialylation to Fc glycans in IVIg, monoclonal antibodies, and other recombinant Fc-containing proteins, in a presentation entitled "Embracing Complexity: Understanding IVIg to Rationally Engineer Novel Therapeutics". The presentation will be given by Tony Manning, Ph.D., Vice President of Research at Momenta, at 12:10 pm on Monday, May 5, 2014 at the PEGS annual meeting in Boston.
Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor Conferences
GlobeNewswire - Wed Apr 30, 3:12PM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at three upcoming investor conferences.
25.9% Return Seen to Date on SmarTrend Momenta Pharmaceuticals Call (MNTA)
Comtex SmarTrend(R) - Mon Apr 28, 5:04PM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 2 months, Momenta Pharmaceuticals has returned 25.85% as of today's recent price of $10.97.
Teva's Copaxone: Perspectives From a Patient and Investor
Anders Bylund, The Motley Fool - Motley Fool - Fri Apr 25, 1:30PM CDT
I was diagnosed with multiple sclerosis five years ago. My neurologist asked me to choose one of the classic CRAB (Copaxone, Rebif, Avonex, or Betaseron) therapies, and I settled on Teva Pharmaceutical Industries ' blockbuster Copaxone treatment....
Global Metastatic Pancreatic Cancer Therapeutics Pipeline Review 2014 - Analysis of 27 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gctlqw/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Adherex Technologies Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - FibroGen, Inc. - Novartis AG - Pfizer Inc. - Celgene Corporation - Bayer AG - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Insys Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - AB Science - Oncovir, Inc. - ParinGenix, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. Drug Profiles - paclitaxel albumin-bound - irinotecan sucrosofate liposomal - masitinib - cisplatin liposomal - cisplatin - refametinib - selumetinib sulfate - trametinib dimethyl sulfoxide - docetaxel - paclitaxel albumin-bound - ganetespib - RX-0201 - irinotecan sucrosofate liposomal - PGX-100 - lurbinectedin - yttrium Y 90 clivatuzumab tetraxetan - Cancer Inhibitor Macrobeads - TL-118 - LY-2090314 - hydroxychloroquine - LY-2495655 - PEGPH-20 - M-402 - pentamidine isethionate - veliparib - galunisertib - ADH-1 - FG-3019 - demcizumab - LCL-161 For more information visit http://www.researchandmarkets.com/research/gctlqw/metastatic
Supreme Court Denies Teva's Request - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 3:35PM CDT
The U.S. Supreme Court denied Teva's appeal of a decision from the U.S. Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 covering Teva's relapsing-remitting multiple sclerosis (RRMS) product, Copaxone 20mg/mL.
Shares of MNTA Down 21.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 21, 11:04AM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 2 months, Momenta Pharmaceuticals has returned 21.12% as of today's recent price of $11.67.
Why Teva (TEVA) Stock Is Lower
at The Street - Mon Apr 21, 7:38AM CDT
Shares of Teva Pharmaceuticals (TEVA) are down in pre-market trade after U.S. Supreme Court Chief Justice Roberts rejected the company's bid to block generic versions of its Copaxone multiple-sclerosis drug while the court hears the company's appeal...
Court declines to block drug ruling in patent case
By SAM HANANEL - AP - Fri Apr 18, 3:39PM CDT
WASHINGTON (AP) — Supreme Court Chief Justice John Roberts on Friday declined to temporarily block a lower court ruling that opens the world's best-selling multiple sclerosis drug to competition from generic rivals next month.
AMAG Pharmaceuticals Announces Appointment of Jim Sulat to Its Board of Directors and the Transition of Chairman Role to Gino Santini
GlobeNewswire - Wed Apr 16, 6:49PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new appointments to its board of directors. Current board member, Gino Santini, has been elected, by unanimous vote, to chairman of the board of directors, effective immediately, taking over for Mike Narachi. Mr. Narachi informed the board that, after eight years of service, he has decided not to stand for re-election at this year's upcoming annual shareholder meeting in May 2014. In addition, James R. Sulat has been elected to serve as a new member of the board of directors, effective immediately.
World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others
M2 - Wed Apr 16, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5qb5x5/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others), predicts a market of nearly $5 billion dollars in the next five years. It's not the first prediction that has been made about the market for generic forms of biopharmaceutical drugs, but according to this report a multi-billion dollar market for biosimilars will arrive in the next five years. The healthcare organization says it's in almost everyone's interest - payors, governments, providers and patients seeking low-cost alternatives to the most expensive and effective therapies. The generic biologic drug market presents many more challenges than the traditional generic market and regulatory restrictions remain. Generic biological drugs are more difficult to produce and a few firms have the expertise. Unlike generics, they are not the exact same as the brand, they have a similar structure and function. Insulin, blood products and monoclonal antibodies (mAbs) are expected to show the most potential for generic equivalent products with blood products leading in revenues. The EU is the first in the world to have defined a policy and legal framework for biosimilars. Absence of such regulation and biosimilars approval process in other countries, in particular in the United States, can lead to a competitive advantage to the EU biosimilars industry, according to the report. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others).contains predictions of biosimilar markets in certain biologic drug segments, as well as market by regions. The report contains specific forecasts for each type of biopharmaceutical and breaks out forecasts by region. Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3Sbio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Biopartners Gmbh - Bio Sidus S.A. - Bioxpress Therapeutics S.A - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy'S Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals Usa, Inc - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance Genemedix Plc - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International Gmbh - Sandoz International Gmbh - Stada Arzneimittel Ag - Teva Pharmaceutical Industries, Ltd. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/5q...rld_market
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 15, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Momenta Pharmaceuticals Announces Date of First Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Apr 15, 3:05PM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2014 before the U.S. financial markets open on Tuesday, May 6, 2014.
The Supreme Court Will Decide the Fate of a Blockbuster
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
Recently, Teva Pharmaceuticals lost a patent lawsuit over its multiple sclerosis drug Copaxone, which makes up a crucial 40% of the company's income. However, the U.S. Supreme Court has announced that it will hear Teva's appeal of this Appeals...
Momenta Pharmaceuticals Down 29.9% Since SmarTrend Downtrend Call (MNTA)
Comtex SmarTrend(R) - Fri Apr 11, 10:00AM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 1 month, Momenta Pharmaceuticals has returned 29.91% as of today's recent price of $10.37.
